TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Visual abstract | Phase II trial of glofitamab following obinutuzumab pretreatment in patients with R/R DLBCL

Mar 28, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in DLBCL.


The Lymphoma Hub is delighted to present a visual abstract summarizing key data from a phase II trial (NCT03075696) investigating the safety and efficacy of fixed-duration glofitamab monotherapy following pretreatment with obinutuzumab in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Glofitamab, a CD20 and CD3 bispecific monoclonal antibody that binds to CD20 b-cells and CD3 T-cells, leads to the engagement and redirection of a patient’s existing T-cells to eliminate malignant B-cells. Obinutuzumab is an anti-CD20 monoclonal antibody used in this study to mitigate cytokine release syndrome. The Lymphoma Hub has previously published an article and an interview on the phase I part of this study.


Visual Abstract

To download this visual abstract, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content